Genprex, Inc. — Form 8-K Summary
Filing date: October 28, 2026. This current report covers an announcement under Item 8.01; it is not a quarterly or annual financial report.
Business context and announced research
Genprex announced that research from its sponsored collaboration with Meharry Medical College will be presented at the Gerontological Society of America 2026 Annual Scientific Meeting, November 4–7, 2026. The poster, “TUSC2 Gene Therapy in Humans Induces a Cellular-Resilience Program,” is scheduled for the November 4 late-breaking poster session. Genprex Chief Medical Officer Mark S. Berger is the presenter.
The research explores TUSC2, the tumor suppressor gene used in Genprex’s lead oncology candidate REQORSA (quaratusugene ozeplasmid), in relation to mitochondrial biology, cellular resilience, and aging-related processes. Genprex says the collaboration began in 2024 and that additional research is intended to expand this work. The filing does not provide study data, methods, or detailed results.
Financial information and period comparisons
This 8-K provides no revenue, profit, cash-flow, margin, debt, liquidity, or other financial metrics, and no comparison with a prior period. It contains no financial guidance.
Outlook, risks, and contingencies
Genprex says the research may inform evaluation of potential applications beyond oncology, but emphasizes that additional research is needed to determine whether findings could support future therapeutic development. The company describes oncology and diabetes as established development priorities.
The filing’s forward-looking-statement caution identifies risks including clinical, regulatory, manufacturing, and commercialization execution; the outcomes of research and product candidates; strategic prioritization; access to capital and long-term liquidity; ability to continue as a going concern and meet Nasdaq listing requirements; third-party performance; and intellectual property. The filing does not report a new contingency or financial commitment related to the collaboration.
Important facts for investors to verify
- Review the poster and underlying data when available; the 8-K itself does not disclose detailed findings.
- Track whether further research supports any potential therapeutic application beyond oncology and whether Genprex reports development plans for it.
- Consult Genprex’s latest periodic filings for current financial condition, liquidity, going-concern risks, and Nasdaq compliance status.
- Assess updates on REQORSA and the company’s oncology and diabetes programs, including clinical and regulatory milestones.